SLU-PP-332
SLU-PP-332
Experimental Exercise-Mimetic Compound — ERRα/β/γ Agonist
SLU-PP-332 is a synthetic small-molecule compound, not a peptide, developed as a research tool for studying estrogen-related receptors (ERRα, ERRβ, and ERRγ). These nuclear receptors play important roles in mitochondrial function, oxidative metabolism, fatty-acid utilization, and exercise-responsive gene expression.
Mechanism of Action
SLU-PP-332 acts as a pan-ERR agonist, activating all three ERR subtypes, with its strongest activity toward ERRα. ERR signaling regulates genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation, and cellular energy metabolism.
Because of this mechanism, researchers have described SLU-PP-332 as an “exercise mimetic”—a compound capable of activating some molecular pathways normally stimulated by aerobic exercise.
Research Findings
⚡ Mitochondrial FunctionIn skeletal-muscle cells, SLU-PP-332 increased mitochondrial respiration and expression of ERR-regulated metabolic genes. Animal studies also found increased mitochondrial content in skeletal muscle.
🏃 Exercise CapacityIn mouse studies, treatment increased oxidative type IIa muscle fibers and improved exercise endurance. Importantly, these findings are preclinical and do not establish equivalent effects in humans.
🔥 Energy Expenditure & Fatty-Acid OxidationResearch in obese mouse models found increased energy expenditure and fatty-acid oxidation, accompanied by reduced fat accumulation and improved insulin sensitivity.
🧬 Metabolic ResearchAdditional animal research has investigated SLU-PP-332 in cardiac metabolism and kidney aging, including effects involving mitochondrial function and metabolic gene expression.
Potential Research Applications
SLU-PP-332 may be useful for laboratory research involving:
Mitochondrial metabolism
Oxidative phosphorylation
Fatty-acid oxidation
Exercise-responsive gene expression
Skeletal-muscle metabolism
Energy expenditure
ERRα/ERRβ/ERRγ signaling
Metabolic disease models
Exercise-mimetic drug discovery
Product Highlights
Compound: SLU-PP-332
Classification: Synthetic small molecule
Target: ERRα / ERRβ / ERRγ
Primary research interest: Mitochondrial and metabolic signaling
Research stage: Preclinical
Not a peptide
Research has been conducted primarily in cell and animal models
Important Research Note
As of 2026, the published evidence remains preclinical. A 2026 analytical study specifically investigated SLU-PP-332 metabolites for potential doping-control applications, reflecting growing interest in the compound but not evidence of established human safety or efficacy.
Research Use Only
For laboratory research use only. Not for human consumption or use in humans or animals. This product is not intended to diagnose, treat, cure, or prevent any disease or medical condition.
Website positioning: I would create a separate “Research Compounds / Metabolic Research” category for SLU-PP-332 rather than placing it with your peptides. Calling it a peptide would be scientifically inaccurate—it is a small-molecule ERR agonist.